Overview

* Privia Health ( PRVA ) Q3 revenue grows 32.5% yr/yr but misses analyst expectations

* Adjusted EBITDA for Q3 beats consensus

* Company raises FY'25 guidance above high end for key metrics

Outlook

* Privia Health ( PRVA ) raises FY'25 revenue guidance to $2.05 bln-$2.1 bln

* Company expects FY'25 adjusted EBITDA of $118 mln-$121 mln

* Privia Health ( PRVA ) anticipates ending FY'25 with at least $410 mln in cash

Result Drivers

* VALUE-BASED CARE - Strong results in Medicare Shared Savings Program and other value-based care arrangements contributed to Q3 performance

* PRACTICE COLLECTIONS - Practice collections increased 27.1% compared to 3Q'24, supporting revenue growth

* PROVIDER GROWTH - Implemented providers grew 13.1% compared to 3Q'24, enhancing service capacity

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Miss $580.40 $781.95

Revenue mln mln (12

Analysts

)

Q3 EPS $0.05

Q3 Net $6.90

Income mln

Q3 Beat $38.20 $28.15

Adjusted mln mln (16

EBITDA Analysts

)

Q3 $14.40

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 18 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the healthcare facilities & services peer group is "buy"

* Wall Street's median 12-month price target for Privia Health Group Inc ( PRVA ) is $30.50, about 18% above its November 5 closing price of $25.02

* The stock recently traded at 85 times the next 12-month earnings vs. a P/E of 70 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)